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Although the importance of the ARF tumor suppres-
sor in p53 regulation is well established, numerous
studies indicate that ARF also suppresses cell growth
in a p53/Mdm2-independent manner. To understand
the mechanism of ARF-mediated tumor suppression,
we identified a ubiquitin ligase, ARF-BP1, as a key
factor associated with ARF in vivo. ARF-BP1 harbors
a signature HECT motif, and its ubiquitin ligase activ-
ity is inhibited by ARF. Notably, inactivation of ARF-
BP1, but not Mdm2, suppresses the growth of p53
null cells in a manner reminiscent of ARF induction.
Surprisingly, in p53 wild-type cells, ARF-BP1 directly
binds and ubiquitinates p53, and inactivation of en-
dogenous ARF-BP1 is crucial for ARF-mediated p53
stabilization. Thus, our study modifies the current
view of ARF-mediated p53 activation and reveals that
ARF-BP1 is a critical mediator of both the p53-inde-
pendent and p53-dependent tumor suppressor func-
tions of ARF. As such, ARF-BP1 may serve as a po-
tential target for therapeutic intervention in tumors
regardless of p53 status.
Introduction
The p53 protein has been described as a “guardian of
the genome” because of its crucial role in coordinating
cellular responses to stress (Lane, 1992; Levine, 1997).
The antiproliferative effects of p53 are imparted through
a variety of mechanisms that include cell cycle arrest,
apoptosis, and cellular senescence/aging (Vogelstein
et al., 2000; Lowe and Sherr, 2003). p53 can be thought
of as the central node of a regulatory circuit that moni-
tors signaling pathways from diverse sources, including
DNA damage responses (e.g., ATM/ATR activation), ab-
normal oncogenic events (e.g., Myc or Ras activation),
and everyday cellular processes (e.g., growth factor
stimulation) (Giaccia and Kastan, 1998; Prives and Hall,
1999; Vousden and Lu, 2002; Brooks and Gu, 2003).
While p53 mutations have been documented in more
than half of all human tumors (Hollstein et al., 1999),
defects in other components of the p53 pathway, such*Correspondence: wg8@columbia.eduas the ARF tumor suppressor, are observed in tumor
cells that retain wild-type p53 (Sherr, 2001; Sharpless
and DePinho, 2004). Thus, inactivation of the p53 path-
way appears to be a common, if not universal, feature
of human cancer.
The cellular functions of p53 are rapidly activated in
response to stress. Although the mechanisms of p53
activation are not fully understood, they are generally
thought to entail posttranslational modifications of p53,
mainly including ubiquitination, phosphorylation, and
acetylation (Brooks and Gu, 2003; Giaccia and Kastan,
1998). Ubiquitination of p53 was first discovered in pap-
illomavirus-infected cells, where p53 degradation is
mediated by the viral E6 protein and a HECT domain-
containing ubiquitin ligase called E6-AP (Munger and
Howley, 2002). In normal cells, Mdm2, a RING finger
oncoprotein, acts as a specific E3 ubiquitin ligase for
p53 (Haupt et al., 1997; Honda et al., 1997; Kubbutat et
al., 1997; Fuchs et al., 1998; Fang et al., 2000), which,
if malignantly activated, has the potential to counteract
the tumor suppressor functions of p53 (Michael and
Oren, 2003). The critical role of Mdm2 in regulating p53
is best illustrated by studies carried out in mice where
inactivation of p53 was shown to completely rescue the
embryonic lethality caused by loss of Mdm2 function
(Jones et al., 1995; Montes de Oca Luna et al., 1995).
Although earlier studies suggested that Mdm2 is the
primary factor controlling p53 turnover, there is growing
evidence that p53 degradation is more complex than
originally anticipated. We recently found that Mdm2 dif-
ferentially catalyzes either monoubiquitination or poly-
ubiquitination of p53 in a dosage-dependent manner (Li
et al., 2003). It seems likely that these distinct mecha-
nisms are exploited in different physiological settings.
For example, Mdm2-mediated polyubiquitination and
nuclear degradation may play a critical role in sup-
pressing p53 function during the latter stages of a DNA
damage response or when Mdm2 is malignantly over-
expressed (Xirodimas et al., 2001a; Shirangi et al.,
2002). On the other hand, Mdm2-mediated monoubiqu-
itination and subsequent cytoplasmic translocation of
p53 may represent an important means of p53 regula-
tion in unstressed cells, where Mdm2 is maintained at
low levels (Freedman et al., 1999; Stommel et al., 1999;
Boyd et al., 2000; Geyer et al., 2000). Moreover, deubiq-
uitination of either p53 or Mdm2 by HAUSP is appa-
rently a critical event in these dynamic processes (Li et
al., 2004; Cummins et al., 2004), and additional cellular
factors are necessary to facilitate p53 degradation in
normal cells. Indeed, it was recently reported that the
ubiquitin ligases COP1 and Pirh2 are directly involved
in p53 degradation (Leng et al., 2003; Dornan et al.,
2004). Taken together, these studies suggest that, while
Mdm2 is a key regulator of p53 function, p53 degrada-
tion is mediated through both Mdm2-dependent and
Mdm2-independent pathways in vivo.
ARF (known as p14ARF in humans and p19ARF in
mouse) was originally identified as an alternative tran-
script of the Ink4a/ARF tumor suppressor locus, a gene
that encodes the p16Ink4a inhibitor of cyclin-dependent
Cell
1072kinases (Sherr, 2001). By virtue of its unique first exon, a
the ARF transcript encodes a protein that is unrelated f
to p16Ink4a (Quelle et al., 1995). Nevertheless, ARF, like a
p16Ink4a, exhibits tumor suppressor functions, as dem- m
onstrated by the tumor susceptibility phenotype of
p14ARF-deficient mice (Kamijo et al., 1997). ARF sup- R
presses aberrant cell growth in response to oncogene
activation, at least in part, by inducing the p53 pathway I
(Sherr, 2001; Sharpless and DePinho, 2004). The ARF o
induction of p53 appears to be mediated through f
Mdm2, since overexpressed ARF interacts directly with T
Mdm2 and inhibits its ability to promote p53 degrada- t
tion (Pomerantz et al., 1998; Zhang et al., 1998; Kamijo A
et al., 1998). Interestingly, the mechanisms by which A
ARF modulates the Mdm2/p53 pathway appear to be a
complex. On one hand, ARF is predominately a nucleo- m
lar protein that can stabilize nucleoplasmic p53 by p
binding and sequestering Mdm2 in the nucleolus (We- p
ber et al., 1999). On the other hand, nucleoplasmic c
forms of ARF also appear to activate p53 function a
(Llanos et al., 2001; Lin and Lowe, 2001) by directly in- m
hibiting the ubiquitin ligase activity of Mdm2 (Honda (
and Yasuda, 1999; Midgley et al., 2000). t
Notably, ARF also has tumor suppressor functions A
that do not depend on p53 or Mdm2. For example, ARF t
can induce cell growth arrest in tumor cells that lack a d
functional p53 gene (Normand et al., 2005; Yarbrough s
et al., 2002; Eymin et al., 2003; Weber et al., 2000; t
Rocha et al., 2003; Korgaonkar et al., 2002) or a gene
encoding the p21 cyclin-dependent kinase inhibitor, a e
key transcriptional target of p53 (Modestou et al., s
2001). ARF can also suppress the proliferation of MEFs b
lacking both Mdm2 and p53 (Weber et al., 2000; Kuo t
et al., 2003). Consistent with these findings, the tumor a
susceptibility of triple knockout mice that lack Arf, p53, p
and Mdm2 is significantly greater than that associated k
with mice lacking any one of these genes alone (Weber w
et al., 2000). Moreover, it was recently shown that ARF 2
suppresses the growth, progression, and metastasis of (
mouse skin carcinomas through both p53-dependent k
and p53-independent pathways (Kelly-Spratt et al.,
e
2004). Together, these studies imply the existence of
H
distinct downstream factors that mediate the p53-inde-
s
pendent functions of ARF. Indeed, this notion is also
t
supported by the fact that p53 is not required for the
edevelopmental eye abnormalities with failed hyaloid
dvascular system displayed by ARF−/− mice (McKeller et
(al., 2002). Nevertheless, the identity of these factors
aand the mechanisms by which they mediate p53-inde-
1pendent tumor suppression by ARF are not well under-
dstood.
tTo elucidate the p53/Mdm2-independent functions of
ARF, we purified naturally formed ARF-containing pro-
Itein complexes from p53 null human cells and identified
EARF-BP1, a HECT (homology to E6-AP C terminus)-
Pcontaining ubiquitin ligase, as a major component of
sthese complexes. ARF-BP1 directly binds ARF, and its
mubiquitin ligase activities are strongly inhibited by ARF.
dSignificantly, inactivation of ARF-BP1 induces cell growth
Uarrest in p53 null cells, indicating that ARF-BP1 is a
ncritical mediator of the p53-independent pathway of
wARF tumor suppression. Surprisingly, inactivation of
rARF-BP1 in p53-positive cells induces p53 stabilization
aand activates a p53-dependent apoptotic response,implying that, in addition to Mdm2, ARF-BP1 also actss a key factor in ARF-mediated p53 activation. These
indings identify a novel regulatory pathway that medi-
tes both the p53-independent and p53-dependent tu-
or suppressor functions of ARF.
esults
dentification of ARF-BP1 as a Major Component
f ARF-Associated Nuclear Complexes
rom p53 Null Cells
o identify the in vivo targets for ARF-mediated func-
ions, we used an epitope-tagging strategy to isolate
RF-containing protein complexes from human cells.
lthough we have used this approach previously (Gu et
l., 1999; Luo et al., 2000; Nikolaev et al., 2003), several
odifications of the method were introduced to im-
rove the stoichiometry of the protein complexes. In
articular, we generated a derivative of the human lung
arcinoma p53 null H1299 cell line that stably expresses
double-tagged human ARF protein containing N-ter-
inal HA and C-terminal Flag epitopes (HA-ARF-Flag)
Figure 1A). Furthermore, to avoid nonphysiological in-
eractions that might occur in cells that overexpress
RF, we opted to use H1299 derivatives that express
he ectopic ARF protein at levels similar to those of en-
ogenous ARF (Figure 1B). Thus, the composition and
toichiometry of the tagged protein complexes are likely
o reflect those of native ARF complexes.
To isolate protein complexes containing ARF, nuclear
xtracts from the stable cell lines were sequentially
ubjected to affinity chromatography on M2 (Flag anti-
ody) agarose beads and an HA-affinity column. Finally,
he bound proteins were fractionated by SDS-PAGE
nd visualized by silver staining (Figure 1C). As ex-
ected, we identified B23/nucleophosmin (NPM), a
nown ARF binding protein (Itahana et al., 2003; Bert-
istle et al., 2004; Brady et al., 2004; Korgaonkar et al.,
005), as a specific component of the ARF complexes
Figure 1C). In addition, a major protein band of w500
Da also copurified with ARF from HA-ARF-Flag-
xpressing H1299 cells (lane 2) but not from parental
1299 cells (lane 1), suggesting that this protein is a
pecific binding partner of ARF. Thus, we designated
his protein as ARF-BP1 (ARF binding protein 1). Inter-
stingly, however, significant levels of Mdm2 were not
etected in these complexes by Western blot analysis
data not shown), and mass spectrometric analysis of
dditional minor bands that copurified with ARF (Figure
C) failed to identify Mdm2 sequences. Thus, these
ata suggest that ARF-BP1 is a major component of
he ARF-associated complexes in these cells.
nitial Characterization of the Ubiquitin
3 Ligase ARF-BP1
eptide sequencing of the ARF-BP1 band by mass
pectrometry identified two peptide sequences that
atched a single, partial cDNA clone in the GenBank
atabase. A small fragment of this protein (named
REB1) was previously reported to bind the preprody-
orphin gene promoter, but its biological functions
ere not understood (Gu et al., 1994). Therefore, by
apid amplification of cDNA ends (RACE) and homology
lignment with the partial cDNA sequences in the data-base, we assembled a full-length cDNA for human ARF-
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jor Component of the ARF-Associated
Nuclear Complexes in Human Cells
(A) Schematic representation of the HA-ARF-
Flag protein.
(B) The expression levels of HA-ARF-Flag
and endogenous ARF in ARF stable lines.
Western blot analysis of cell extracts from
parental H1299 cell line (lane 1), ARF stable
cell line clone 1 (lane 2), and ARF stable cell
line clone 2 (lane 3) with an anti-ARF an-
tibody.
(C) Silver staining of affinity-purified ARF
complexes from a nuclear extract of the HA-
ARF-Flag/H1299 stable cell line (lane 2) and
a control elute from a parental H1299 nuclear
cell extract (lane 1). Specific ARF-interacting
protein bands were analyzed by mass spec-
trometry, and the p500/ARF-BP1 and B23/
NPM (Nucleophosmin) peptide sequences
are presented.BP1 cDNA (accession number AY772009). This cDNA
encodes a protein of 4374 amino acids (Figure 2A and
Figure S1 in the Supplemental Data available with this
article online), which is more than 3000 residues longer
than the published UREB1 sequence (Gu et al., 1994).
The C-terminal sequences of ARF-BP1 possess a
signature motif (the HECT domain) common to a num-
ber of ubiquitin E3 ligases (Figures 2A and 2B). This
motif was first identified in E6-AP, a cellular E3 ligase
that, when bound to the E6 protein of oncogenic human
papillomaviruses, acquires the ability to bind and ubiq-
uitinate the p53 tumor suppressor (Scheffner et al.,
1993; Munger and Howley, 2002). The HECT domain,
which encompasses about 350 amino acids, harbors a
cysteine residue that forms a catalytic thiol ester with
Ub and is essential for the enzymatic activity of HECT
proteins (Pickart, 2001; Huang et al., 1999). ARF-BP1
also contains the ubiquitin-associated domain (UBA)
(Figure 2A and Figure S2), a small sequence motif found
in various proteins linked to the ubiquitination pathway,
such as the DNA repair protein Rad23 or the Cbl ubiq-
uitin ligase (Hicke and Dunn, 2003; Buchberger, 2002).
A WWE domain was also identified, which may be in-
volved in protein-protein interactions (Aravind, 2001).
Northern blot analysis showed that the ARF-BP1 mRNA
is broadly expressed in various types of human tissue
(Figure 2C).
ARF-BP1 Interacts with ARF Both
In Vitro and In Vivo
To confirm the physical interaction between ARF and
ARF-BP1, we first tested whether ARF-BP1 binds ARFin vitro. The ARF polypeptide can be roughly divided
into two major functional domains: an N-terminal region
encoded by the unique 1β exon (N-ARF; residues 1–64),
which is critical for ARF-mediated p53 activation as
well as p53-independent ARF functions, and a C-ter-
minal region (C-ARF; residues 65–132), which is not
conserved between human and mouse counterparts
and is of uncertain function. As shown in Figure 3A,
35S-labeled ARF-BP1 (1–1014), a polypeptide compris-
ing the N-terminal 1014 residues of ARF-BP1, did not
associate with immobilized GST-ARF (lanes 7–9, Figure
3A). In contrast, however, 35S-labeled ARF-BP1 (1015–
4574) strongly bound both full-length ARF (GST-ARF;
lane 3) and the N-terminal ARF domain (GST-N-ARF;
lane 5) but not the C-terminal ARF domain (GST-C-
ARF; lane 6) or GST alone (lane 2). Interestingly, ARF-
BP1 weakly bound the ARF mutant GST-ARF1–14
(lane 4), indicating that deletion of the N-terminal 14
amino acids of ARF significantly compromises but does
not eliminate the ARF/ARF-BP1 interaction.
To confirm the interaction between ARF and ARF-
BP1 in vivo, we raised an affinity-purified polyclonal an-
tiserum against 192 amino acid segment of ARF-BP1
(residues 3435–3626) that shows no apparent homol-
ogy with other known proteins. Upon Western blot
analysis, this antibody specifically detects ARF-BP1
polypeptides in human cells (lane 1, Figure 3B). To in-
vestigate the interaction between endogenous ARF-
BP1 and ARF polypeptides, cell extracts from native
H1299 cells were immunoprecipitated with α-ARF-BP1
or with the control IgG. As expected, Western blot
analysis revealed that this antibody immunoprecipi-
Cell
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HECT Motif, WWE, and a UBA Domain
(A) Schematic representation of the ARF-
BP1 polypeptides.
(B) An alignment of the HECT domain of hu-
man ARF-BP1 with mouse ARF-BP1 and hu-
man E6-AP. Homologous amino acid resi-
dues are highlighted in outline and shadow.
(C) ARF-BP1 is widely expressed in different
types of human tissue. A multiple tissue
Northern filter was hybridized with ARF-BP1
(upper) or actin (lower) cDNA probes.tated endogenous ARF-BP1 (lane 3, upper panel, Fig- p
uure 3B); more importantly, ARF was clearly detected in
the immunoprecipitations obtained with the α-ARF- f
iBP1 antiserum (lane 3, lower panel, Figure 3B) but not
the control IgG (lane 2, lower panel, Figure 3B). Con- (
rversely, endogenous ARF-BP1 was readily immuno-
precipitated with the ARF-specific antibody (lane 3, Fig- t
aure 3C), but not with a control antibody (lane 2, Figure
3C). These data indicate that ARF and ARF-BP1 in- C
uteract both in vitro and in vivo.
A
AThe HECT Domain of ARF-BP1 Has a Ubiquitin
Ligase Activity that Is Strongly Inhibited by ARF
Although ARF can stabilize p53 by sequestering Mdm2 I
Rin the nucleolus (Weber et al., 1999), it is well accepted
that ARF can also stabilize p53 by directly inhibiting the A
cenzymatic activity of Mdm2 (Sherr, 2001; Honda and
Yasuda, 1999; Midgley et al., 2000). Given that ARF- M
nBP1 contains a HECT motif (Figure 2A), we examined
whether ARF can also inhibit the ubiquitin ligase activ- W
mity of ARF-BP1. To do so, we first tested whether ARF-
BP1 displays enzymatic activity in an in vitro assay b
pusing purified components. Therefore, the GST-ARF-
BP1 (3760–4374) polypeptide, which includes the HECT h
ddomain of ARF-BP1, was expressed in bacteria andurified to near homogeneity. As indicated in Figure 3D,
biquitin-conjugated forms of ARF-BP1 were readily
ormed when GST-ARF-BP1 (3760–4374) was incubated
n the presence of ubiquitin, E1, and an E2 (UbcH5c)
lane 2). Notably, this activity was strongly repressed by
ecombinant full-length ARF (lane 3). Moreover, consis-
ent with the binding results (Figure 3A), the evolution-
rily conserved N-terminal region of ARF, but not the
-terminal region, inhibited ARF-BP1-mediated auto-
biquitination (lanes 4 and 5). These data suggest that
RF functions as a potent enzymatic inhibitor of the
RF-BP1 ubiquitin ligase activity.
nactivation of ARF-BP1 Induces Cell Growth
epression in p53 Null Cells
lthough numerous studies have shown that in normal
ells ARF stabilizes and activates p53 by inhibiting
dm2 function, ARF can also inhibit the growth of p53
ull cells (Eymin et al., 2003; Yarbrough et al., 2002;
eber et al., 2000). Since we identified ARF-BP1 as the
ajor ARF binding protein from p53 null cells, it is feasi-
le that ARF induces p53-independent growth sup-
ression by inhibiting ARF-BP1 function. To test this
ypothesis, we examined whether inactivation of en-
ogenous ARF-BP1 also represses cell growth in p53
Regulation of the p53/ARF Pathway by ARF-BP1
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BP1-Mediated Ubiquitin Ligase Activity Is Inhibited by ARF
(A) Direct interactions of ARF-BP1 with GST-ARF. The wild-type
GST-ARF full-length protein (GST-ARF) (lanes 3 and 9), the mutant
GST-ARF (GST-ARF1–14) (lane 4), the N terminus of ARF protein
(1–64) (lane 5), the C terminus of ARF (65–132) (lane 6), or GST
alone (lanes 2 and 8) was used in a GST pull-down assay either
with in vitro translated 35S-labeled ARF-BP1 (1015–4374) (lanes
1–6), or with in vitro translated 35S-labeled ARF-BP1 (1–1014) (lane
7–9).
(B) Coimmunoprecipitation of ARF with ARF-BP1 from H1299 cells.
Western blot analysis of indicated whole-cell extract (WCE) (lane 1)
and immunoprecipitates with an ARF-BP1-specific antibody (lane
3) or a control IgG (lane 2) by anti-ARF monoclonal antibody (lower)
or anti-ARF-BP1 antibody (top).
(C) Coimmunoprecipitation of ARF-BP1 with ARF from H1299 cells.
Western blot analysis of whole-cell extract (WCE) (lane 1) or immu-
noprecipitates with anti-ARF polyclonal antibody (lane 3) or a con-
trol antiserum (lane 2) by a ARF-BP1-specific antibody (lower) or
anti-ARF monoclonal antibody (top).
(D)The ubiquitination activity of ARF-BP1 is inhibited by ARF. West-
ern blot analysis of the ubiquitin conjugates by anti-GST antibody.
The in vitro ubiquitination assay was set up by incubating GST-
ARF-BP1 (3760–4374) with E1, E2 (His-UBCH5a), and ubiquitin
(lane 2), or in the presence of GST-ARF (lane 3), GST-NARF (lane 4),
or GST-CARF (lane 5), respectively.null cells in a manner reminiscent of ARF induction. For
this purpose, p53 null H1299 cells were transfected
with either an ARF-BP1-specific (ARF-BP1-RNAi1) or a
control (GFP-RNAi) siRNA. As shown in Figure 4A, the
levels of endogenous ARF-BP1 polypeptides were se-
verely reduced after three consecutive transfections
(upper panels, lane 3 versus lane 2) with ARF-BP1-
RNAi1. As expected, the steady-state levels of p21 and
Mdm2, two known transcriptional targets of p53, were
unaffected by ARF-BP1 ablation. Strikingly, however,ARF-BP1-RNAi treatment significantly reduced the
growth rate of these cells (Figure 4B), suggesting that
ARF-BP1 inactivation induces cell growth repression.
Moreover, these cells grew slightly faster when endoge-
nous Mdm2 expression was diminished with RNAi in
these cells (Figures 4A and 4B). By monitoring BrdU
incorporation (Figure 4C), we again found that ARF-BP1
knockdown inhibits, while Mdm2 knockdown modestly
promotes, the growth of p53 null cells. Similar results
were also obtained with another p53 null cell line
(SaoS-2; Figure S3) and another siRNA (ARF-BP1-
RNAi2) that recognizes a different region of the ARF-
BP1 mRNA (Figure S4).
Interestingly, ARF-mediated cell growth in p53 null
cells is not well characterized. For example, it was ini-
tially observed that ARF overexpression induces G1 ar-
rest in p53/Mdm2 double null MEF cells (Weber et al.,
2000); however, more recent studies show that ARF ex-
pression induces G2/M arrest in a number of p53 null
human cell lines (Normand et al., 2005; Eymin et al.,
2003). To further analyze the nature of cell growth arrest
mediated by ARF-BP1 inactivation in H1299 cells, we
first examined the effect of ARF expression in these
cells. As shown in Figure 4D, ARF expression induced
G2/M accumulation of these cells, but no obvious
apoptotic cells (Sub-G1) were observed (“iii” versus “i”
in Figure 4D). Strikingly, inactivation of ARF-BP1 by
ARF-BP1 RNAi in these cells also led to G2/M arrest at
similar levels (“ii” in Figure 4D). Thus, inactivation of
ARF-BP1 inhibits the growth of these p53 null cells in
a manner reminiscent of ARF induction.
Inactivation of Endogenous ARF-BP1 Stabilizes p53
and Induces p53-Dependent Apoptosis
To investigate the role of the ARF/ARF-BP1 interaction
in p53-positive cells, we tested the functional conse-
quences of ARF-BP1 inactivation in cells expressing
wild-type p53. Thus, we transfected human osteosar-
coma U2OS cells with either an ARF-BP1-specific
siRNA (ARF-BP1-RNAi1) or a control siRNA (GFP-
RNAi); surprisingly, RNAi-mediated knockdown of ARF-
BP1 expression elevated the steady-state levels of en-
dogenous p53 (Figure 5A) and extended the half-life of
p53 polypeptides (Figure 5B and Figure S5). Similarly,
the expression of p21 and BAX, both known transcrip-
tional targets of p53, was strongly induced by ARF-BP1
inactivation (Figure 5A). Significantly, ARF-BP1 ablation
also induced programmed cell death; as shown in Fig-
ure 5C, 32.3% of the ARF-BP1-RNAi1-treated U2OS
cells underwent apoptosis (“II” in Figure 5C), while no
significant apoptosis was observed in the control-
transfected cells (“I” in Figure 5C). These data suggest
that inactivation of ARF-BP1 stabilizes p53 and acti-
vates its mediated functions.
The above results were unexpected given the view
that Mdm2 is the primary mediator of ARF-induced p53
activation. To verify the specific effects induced by
ARF-BP1 ablation, we performed multiple control ex-
periments. Thus, for example, we were able to knock
down endogenous ARF-BP1 expression and again ele-
vate the endogenous levels of p53 by treating cells with
a siRNA (ARF-BP1-RNAi 2) that recognizes a different
region of the ARF-BP1 mRNA, but not with a point mu-
Cell
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BP1, but Not Mdm2, Induces Cell Growth Ar-
rest in p53 Null H1299 Cells
(A) Endogenous ARF-BP1 and Mdm2 pro-
teins were ablated by RNAi. Western blot
analysis of cell extracts of H1299 cells
treated with a control RNAi (GFP-RNAi) (lane
1), Mdm2 RNAi (lane 2), or ARF-BP1 RNAi 1
(lane 3) with the antibodies against ARF-
BP1, Mdm2, p21, and actin.
(B) Overall cell growth of the H1299 cells
treated with a control RNAi (GFP-RNAi),
Mdm2 RNAi, or ARF-BP1 RNAi 1. The cells
were stained with crystal violet 3 days after
siRNA treatment.
(C) The BrdU incorporation of the H1299
cells treated with a control RNAi (GFP-RNAi),
Mdm2 RNAi, or ARF-BP1 RNAi 1. The cells
were labeled and stained 1 day after RNAi
treatment.
(D) Inactivation of ARF-BP1 induces G2M ar-
rest in H1299 cells, similar to overexpres-
sion of ARF. Cell cycle profile of control RNAi
plus control virus treatment (“i”), ARF-BP1
RNAi (“ii”), adenoviral-ARF treatment (“iii”),
and ARF-BP1 RNAi plus adenoviral-ARF
treatment.tant form of the siRNA (ARF-BP1-RNAi 1-mut) (Figure B
lS6; also see Figure S4D). In addition, similar results
were obtained using a variety of different cell lines that R
fretain wild-type p53 function, including MCF-7 human
breast carcinoma cells (Figure S7), A549 human lung l
(adenocarcinoma cells (Figure S7), and normal human
fibroblast cells (NHF-1) (Figure S8). p
iTo further demonstrate the specificity of ARF-BP-
RNAi-mediated effects, we performed the rescue ex- w
Hperiments. We first made a new expression vector for
ARF-BP1, which contains a point mutation at the RNAi1 t
Atargeting region [ARF-BP1(R)] (Figure S9A). Thus, this
mutant is immune to the effect by the ARF-BP1 RNAi1. t
aTo further elucidate the importance of ubiquitin ligase
activity of ARF-BP1, we have also made another mu-
ptant [ARF-BP1M(R)], in which the conserved cysteine
residue at the HECT domain is replaced by alanine (aa o
o4341 C/ A; Figure S9A). By using in vitro ubiquitination
assay, we have confirmed that this mutation at the s
HHECT domain abrogates the ubiquitin ligase activity of
ARF-BP1 (Figure S9B). A
dTo perform the “rescue experiments,” we first con-
ducted the RNAi assay in U2OS cells with ARF-BP1- n
aRNAi1 and then tried to rescue by expressing the ARF-
BP1 mutant [ARF-BP1(R)]. As indicated in Figure 5D, S
pafter the ARF-BP1 RNAi1 treatment, endogenous p53
was stabilized, and p21 was activated; however, ARF- rP1(R) expression reversed the effect on the p53 stabi-
ization and p21 induction induced by the ARF-BP1
NAi1 (lane 3 versus lane 2). Notably, the HECT mutant
orm [ARF-BP1M(R)], which was expressed at similar
evels, failed to rescue the effects (lane 4 versus lane 2)
Figure 5D). We also used this approach for p53-inde-
endent function in H1299 cells. Indeed, the cell growth
nhibition induced by the ARF-BP1 RNAi1 treatment
as rescued by expression of ARF-BP1(R), but not the
ECT mutant form [ARF-BP1M(R)] (Figure S10). Thus,
hese data demonstrate not only the specificity of the
RF-BP1-RNAi-mediated effects but also the impor-
ance of the ubiquitin ligase activity in ARF-BP1-medi-
ted functions.
To prove rigorously that these effects of ARF-BP1 are
53 dependent, we performed the siRNA assay in a pair
f isogenic human colorectal carcinoma lines that do
r do not express wild-type p53 (Bunz et al., 1998). As
hown in Figure 5E, when HCT116 parental cells and
CT116 p53−/− cells were subjected to RNAi treatment,
RF-BP1 knockdown led to stabilization of p53 and in-
uction of p21 in the parental cells, but not in the p53
ull cells. In contrast, the levels of control proteins such
s c-Myc and actin were unaffected by RNAi treatment.
ignificantly, ARF-BP1 ablation induced apoptosis in
arental HCT116 cells, but not in p53 null HCT116 de-
ivatives (Figure S11). As expected, the steady-state
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p53 and Induces p53-Dependent Apoptosis
(A) Endogenous ARF-BP1 was knocked
down by RNAi in human U2OS cells. West-
ern blot analysis of cell extracts of native
U2OS cells (lane 1), the U2OS cells treated
with a control RNAi (GFP-RNAi) (lane 2), or
ARF-BP1 RNAi 1 (lane 3) with the antibodies
against ARF-BP1, p53, p21, bax, and actin.
(B) Inactivation of ARF-BP1 extends the half-
life of endogenous p53 protein. Western blot
analysis of cell extracts with an anti-p53
(DO-1) antibody, from ARF-BP1-RNAi- or
control-RNAi-transfected cells, harvested at
indicated time points (min) after cyclohexa-
mide (CHX) treatment.
(C) Inactivation of ARF-BP1 induces apopto-
sis. U2OS cells transfected with either ARF-
BP1-RNAi or control-RNAi were analyzed for
apoptotic cells (sub-G1) according to DNA
content (PI staining).
(D) ARF-BP1-RNAi-mediated effects are re-
versed by ARF-BP1(R) expression in U2OS
cells. Western blot analysis of cell extracts
of the U2OS cells treated with a control RNAi
(GFP-RNAi) (lane 1), ARF-BP1 RNAi 1 (lane
2), or combination of ARF-BP1 RNAi 1 and
ARF-BP1(R) (lane 3), ARF-BP1 RNAi 1, and
ARF-BP1M(R) (lane 4) with the antibodies
against ARF-BP1, p53, p21, and actin.
(E) Western blot analysis of cell extracts
from parental HCT 116 cells (lanes 1 and 2)
or HCT116-p53−/− cells (lanes 3 and 4)
treated with either control RNAi (lanes 1 and
3) or ARF-BP1-RNAi (lanes 2 and 4), with the
antibodies against ARF-BP1, Mdm2, p53,
p21, Myc, and actin.levels of Mdm2 were also induced by ARF-BP1 inacti-
vation in the parental cells, consistent with the fact that
Mdm2 is a transcription target of p53. Notably, how-
ever, Mdm2 levels in the p53 null cells were unaffected
by ARF-BP1 ablation (Figure 5E), suggesting that inac-
tivation of ARF-BP1 induces p53 stabilization but has
no effect on Mdm2 stabilization. By demonstrating that
ARF-BP1 inactivation is sufficient to stabilize and acti-
vate p53 in normal cells, these data imply that the ARF/
ARF-BP1 interaction may contribute, at least in part, to
p53 activation induced by ARF.
ARF-BP1 Directly Binds and Ubiquitinates p53,
and ARF-BP1-Mediated Ubiquitination
of p53 Is Inhibited by ARF
To elucidate the functional relationship between p53
and ARF-BP1, we examined whether ARF-BP1 can
bind p53 in the absence of ARF. As shown in Figure
6A, 35S-labeled ARF-BP1 (1015–4374) strongly bound
immobilized GST-p53, but not GST alone (lane 3 versus
lane 2). Conversely, no significant binding was detected
between ARF-BP1 and GST-Mdm2 (lane 4). We next
evaluated the in vivo interaction between endogenous
p53 and ARF-BP1 proteins. To this end, cell extracts
from U2OS cells were immunoprecipitated with α-ARF-
BP1 or with the control IgG. As seen in Figure 6B, p53was clearly detected in the immunoprecipitates ob-
tained with the α-ARF-BP1 antiserum (lane 3) but not
the control IgG (lane 2, lower panels). Conversely, en-
dogenous ARF-BP1 was readily immunoprecipitated
with the p53-specific monoclonal antibody DO-1 (lane
3, Figure 7C), but not with a control antibody (lane 2,
Figure 6C). These data indicate that p53 can interact
directly with the ARF-BP1 protein both in vitro and
in vivo.
Since our data show that inactivation of ARF-BP1 in-
duces p53 stabilization, we examined whether ARF-
BP1 directly induces p53 ubiquitination in the absence
of Mdm2. Thus, Flag-p53 was incubated with GST-ARF-
BP1 in the presence of HA-tagged ubiquitin (HA-Ub),
E1, and an E2 (UbcH5c). The ubiquitin-conjugated p53
products of the reaction were then immunoprecipitated
with Flag/M2 beads and visualized by Western analysis
with a p53-specific antibody. As indicated in Figure 6D,
high levels of ubiquitinated p53 were generated by
ARF-BP1 (lane 2). Significantly, ARF-BP1-mediated p53
ubiquitination was strongly repressed in the presence
of ARF (lane 3). Also, consistent with the binding data
shown in Figure 3A, the N-terminal region of ARF
(N-ARF) retained full inhibition of ARF-BP1-mediated
p53 ubiquitination whereas the C-terminal region (C-ARF)





Figure 6. ARF-BP1 Binds and Ubiquitinates p53, and ARF-BP1-
(Mediated Ubiquitination of p53 Is Inhibited by ARF
c
(A) Direct interactions of ARF-BP1 with GST-p53. The GST-p53 pro-
w
tein (lanes 3 and 7), GST-Mdm2 (lanes 4 and 8), or GST alone (lanes
(
2 and 6) was used in a GST pull-down assay with in vitro translated




(B) Coimmunoprecipitation of p53 with ARF-BP1 from U2OS cells.
e
Western blot analysis of whole-cell extract (WCE) (lane 1) or immu-
(
noprecipitates with anti-ARF-BP1-specific antibody (lane 3) or a
M




(C) Coimmunoprecipitation of ARF-BP1 with p53 from U2OS cells.
b
Western blot analysis of indicated whole-cell extract (WCE) (lane 1)
b
and immunoprecipitates with a p53 monoclonal antibody DO-1
(lane 3) or control antibody (lane 2) by anti-ARF-BP1-specific anti-
body (lower) or anti-p53 DO-1 antibody (top). w
(D) ARF-BP1-mediated ubiquitination of p53 is inhibited by ARF. M
After incubation of Flag-p53 with GST-ARF-BP1 (3760–4374) in the
dpresence of E1, E2, and ubiquitin (HA-Ub), the generated p53-ubiq-
puitin conjugates were immunoprecipitated by the Flag/M2 beads
and analyzed by Western blot with anti-p53 DO1 antibody. The re- l
combinant bacteria expressed proteins GST-ARF, N-ARF o
(1–64), or C-ARF (65–132) were added in the reactions shown in b
lanes 3, 4, or 5, respectively.
digure 7. ARF Induces p53 Stabilization in an Mdm2-Independent
anner, and ARF-BP1 Is Critical for ARF-Mediated p53 Stabiliza-
ion in Mdm2 Null Cells
A) ARF stabilizes p53 in Mdm2 null cells. Western blot analysis of
ell extracts from MEF p53/Mdm2-double null cells transfected
ith expression vectors of p53 and ARF with a p53 antibody
DO-1).
B) Inactivation of ARF-BP1 stabilizes p53 in Mdm2 null cells. West-
rn blot analysis of cell extracts from MEF p53/Mdm2 double null
ells transfected with the p53 expression vector together with
ither ARF-BP1 RNAi or Mdm2 RNAi, by a p53 antibody (DO-1).
C) ARF-BP1 is required for ARF-mediated p53 stabilization in
dm2 null cells. Western blot analysis of cell extracts from MEF
53/Mdm2 double null cells transfected with expression vectors of
53 and ARF, together with either ARF-BP1 RNAi or Mdm2 RNAi,
y anti-p53 (DO-1), anti-ARF, anti-ARF-BP1, and anti-GFP anti-
odies.w
that ARF-BP1 is an ubiquitin ligase for p53 and that l
ARF-BP1-mediated ubiquitination of p53 is repressed p
by ARF. p
o
BARF-BP1 Is Critical for ARF-Mediated p53
Stabilization in Mdm2 Null Cells t
tSince ARF-BP1 binds and ubiquitinates p53 in the ab-
sence of Mdm2, it is conceivable that the ARF/ARF- p
cBP1 interaction stabilizes p53 in an Mdm2-independent
manner. To test this hypothesis, we first examined Bhether ARF expression induces p53 stabilization in
dm2 null cells. To this end, we transfected p53/Mdm2
ouble null MEF cells with expression vectors encoding
53 alone, or both p53 and ARF; indeed, p53 protein
evels were significantly elevated in these cells by ARF
verexpression (Figure 7A), indicating that ARF can sta-
ilize p53 in an Mdm2-independent manner.
To verify the role of endogenous ARF-BP1 in p53
egradation in the absence of Mdm2, we examined
hether inactivation of ARF-BP1 is sufficient to stabi-
ize p53 in Mdm2 null cells. For this purpose, Mdm2/
53 double null cells were cotransfected with a p53 ex-
ression vector and siRNAs specific for either ARF-BP1
r Mdm2. Significantly, ablation of endogenous ARF-
P1 expression in the cells caused a marked stabiliza-
ion of p53 (Figure 7B and Figure S12). As expected,
reatment with Mdm2-specific siRNAs had no effect on
53 levels in Mdm2/p53 null cells (lane 3, Figure 7B),
onfirming the specificity of p53 stabilization by ARF-
P1 inactivation.
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involved in the Mdm2-independent p53 stabilization in-
duced by ARF, we examine whether ARF-BP1 is re-
quired for ARF-mediated p53 stabilization in Mdm2 null
cells. Thus, p53/Mdm2 double null cells were cotrans-
fected with ARF-BP1-specific siRNAs and expression
vectors encoding p53 and ARF. As indicated in Figure
7C, the p53 stabilization induced by ARF was clearly
attenuated in ARF-BP1 knockdown cells (lanes 6–9),
suggesting that ARF-BP1 is critical for ARF-mediated
p53 stabilization in these cells. In contrast, ARF-medi-
ated p53 stabilization was intact in cells treated with
Mdm2-specific siRNAs (lanes 2–5, Figure 7C). Taken to-
gether, these results indicate that ARF-BP1 is critical
for the ARF-mediated, Mdm2-independent stabilization
of p53.
Discussion
The present data demonstrate a critical role of ARF-
BP1 in mediating both the p53-dependent and p53-
independent functions of ARF. Here, we show that (1)
ARF-BP1 is the major component of ARF-containing
nuclear complexes in human cells; (2) ARF-BP1 in-
teracts with both ARF and p53, but not with Mdm2; (3)
ARF-BP1 is widely expressed and contains signature
motifs (HECT, WWE, and UBA) commonly associated
with protein ubiquitination; (4) ARF-BP1 has an intrinsic
ubiquitin ligase activity, and this activity is strongly re-
pressed by ARF; (5) inactivation of endogenous ARF-
BP1, but not Mdm2, induces cell growth repression in
p53 null cells in a manner reminiscent of ARF induction;
(6) ARF-BP1 catalyzes ubiquitination of p53 directly,
and inactivation of endogenous ARF-BP1 in p53 wild-
type cells stabilizes p53 and activates p53 function;
and (7) ARF-BP1 is required for ARF-mediated p53 sta-
bilization in Mdm2 nulls. Since ARF can stabilize p53 in
an Mdm2-independent manner, and inactivation of
ARF-BP1 by ARF also induces growth arrest in p53 null
cells, our study significantly modifies the current view
of how ARF mediates its tumor suppressor function
in vivo.
The Role of ARF-BP1 in ARF-Mediated
Activation of p53
While it is widely accepted that ARF is a bona fide tu-
mor suppressor (Sherr, 2001; Sharpless and DePinho,
2004), the first clue that it can activate the p53 pathway
emerged from tissue culture experiments showing that
p53 stabilization is crucial for ARF-mediated function
(Kamijo et al., 1997). At the time, the role of Mdm2 in
ubiquitination and degradation of p53 had recently
been discovered (Haupt et al., 1997; Honda et al., 1997;
Kubbutat et al., 1997). Based primarily on results de-
rived from experiments involving protein overexpres-
sion, this seemingly obvious connection between ARF
and Mdm2 was soon regarded as the primary pathway
for ARF-mediated p53 activation (Sherr, 2001).
However, several lines of evidence indicate that ARF-
mediated activation of p53 is more complicated than
the simple ARF-Mdm2-p53 model. First, the ARF/
Mdm2 interaction was originally defined in experiments
based on Mdm2 overexpression; nevertheless, the steady-state levels of Mdm2 in normal cells are low, and an
interaction between the endogenous ARF and Mdm2
polypeptides in normal cells has not yet been well char-
acterized. Second, while the low levels of Mdm2 that
are commonly observed in normal cells preferentially
catalyze monoubiquitination of p53 (Li et al., 2003), re-
cent studies from Lane’s group indicate that ARF can
only block p53 polyubiquitination but is incapable of
inhibiting Mdm2-mediated monoubiquitination of p53 in
vivo (Xirodimas et al., 2001b). These studies raise a crit-
ical question: how does ARF efficiently stabilize p53 in
the cells where the levels of Mdm2 are low and Mdm2
is not solely responsible for p53 degradation? Our re-
sults on ARF-BP1 implicate a novel Mdm2-independent
pathway for ARF-mediated p53 activation. ARF-BP1
was identified as a major component of ARF-containing
protein complexes, and the interaction between endog-
enous ARF-BP1 and ARF proteins is easily detected in
unstressed cells.
Several recent studies support the notion that p53
degradation is mediated by both Mdm2-dependent and
Mdm2-independent pathways in vivo (Leng et al., 2003;
Dornan et al., 2004). Interestingly, by using RNAi knock-
ing-down approaches, we tended to examine the dif-
ferential effects on p53 stabilization by these known E3
ligases of p53. As expected, inactivation of Mdm2 pro-
moted p53 stabilization, while inactivation of either
COP1 or Pirh2 also modestly stabilized p53. Notably,
inactivation of ARF-BP1 strongly induced p53 stabiliza-
tion and activated p53-mediated transcription (Figure
8A); the levels of p21 and Bax induction induced by
ARF-BP1 RNAi were higher than the levels induced by
other types of E3 siRNAs for p53 (Figure 8A) and very
close to the effects by ARF overexpression (Figure
S13). These data indicate that ARF-BP1 is a major ubiq-
uitin ligase of p53 in human cells and, more importantly,
is also a key target for ARF-mediated tumor suppres-
sor function.
The existence of two distinct pathways for ARF-
mediated p53 activation, one based on the ARF-BP1
ubiquitin ligase and another based on the Mdm2 ubiq-
uitin ligase, allows for more versatile control of p53
functions (Figure 8B) but also raises the question re-
garding their biological significances. For example, the
critical role of Mdm2 in tumorigenesis is well estab-
lished. Gene amplification and protein overexpression
of Mdm2 are found in various types of tumors (Michael
and Oren, 2003). Thus, the ARF-Mdm2 interaction
might be particularly important in the cells expressing
high levels of Mdm2. Through a database search, we
found that the gene encoding ARF-BP1 is localized on
chromosome Xp11.22. Interestingly, we also found that
ARF-BP1 is highly expressed in 80% (16/20) of breast
cancer cell lines, while the expression level of ARF-BP1
in normal breast cells (MCF-10A) is low (Figure 8C),
suggesting a potential role of ARF-BP1 in breast can-
cer tumorigenesis.
The Role of ARF-BP1 in p53-Independent ARF
Tumor Suppression
Although its role in activating p53 is well accepted, ARF
is also found to be mutated or downregulated in tumors
that lack functional p53 (Sherr, 2001). This suggests
Cell
1080Figure 8. ARF-BP1 Is a Critical Mediator of
ARF Tumor Suppressor Function
(A) Reduction of ARF-BP1 has the most sig-
nificant effect on p53 levels when compared
to the known E3 ligases for p53, including
Mdm2, COP1, and Pirh2. Western blot analy-
sis of cell extracts from U2OS treated with
control RNAi (lanes 1), Mdm2 RNAi (lane 2),
COP1 RNAi (lane 3), Pirh2 RNAi (lane 4), and
ARF-BP1 RNAi 1 (lane 5), with the antibodies
against ARF-BP1, Mdm2, Pirh2, p53, p21,
Bax, and actin. The COP1 antibody was not
available.
(B) A model for cooperative controls of the
p53-dependent and p53-independent func-
tions of ARF by ARF-BP1 and Mdm2. See
text for details.
(C) ARF-BP1 expressions in breast cancer
cell lines. Western blot analysis of cell ex-
tracts from a number of breast cancer cell
lines compared with the normal breast cell
line MCF-10A as well as the normal human
fibroblast NHF cell line by anti-ARF-BP1-
specific antibody and anti-actin antibody.that the p53-independent functions of ARF are also crit-
vical for its tumor suppression activity. Consistent with
this notion, a number of studies indicate that ARF can a
Nrepress cell growth in a p53-independent manner (We-
ber et al., 2000; Normand et al., 2005; Rocha et al., e
t2003; Itahana et al., 2003; Eymin et al., 2003; Yarbrough
et al., 2002; Korgaonkar et al., 2002). Based on our ob- a
pservation that ARF-BP1 is the major binding partner of
ARF in p53 null cells, we propose that ARF-BP1 is a m
ccritical mediator of p53-independent ARF functions.
This hypothesis is further supported by the fact that g
dinactivation of ARF-BP1, but not Mdm2, induces cell
growth repression in p53 null cells in a manner reminis- o
lcent of ARF induction.
The precise mechanism by which ARF-mediated reg-
Eulation of ARF-BP1 leads to p53-independent cell
growth arrest needs future investigation. Since ARF- P
BP1 is a bona fide ubiquitin ligase, it is likely that the T
p53-independent functions of ARF involve unidentified t
Menzymatic substrates of ARF-BP1 (Figure 8B). In the
clight of recent studies showing that nucleophosmin/
qB23 and certain ribosomal subunits are involved in the
tregulation of ARF-mediated ribosomal RNA processing
[
(Itahana et al., 2003; Bertwistle et al., 2004), it will be s
interesting to examine whether ARF-BP1 is directly in- c
tvolved in regulating B23 function or ribosomal RNA
sprocessing. Moreover, since the ARF pathway is inti-
smately linked with oncogene activation in vivo (Sherr,
r2001; Sharpless and DePinho, 2004), it will be intriguing
to know whether the ARF/ARF-BP1 interaction, as well P
as the ubiquitin ligase activity of ARF-BP1, is regulated T
cby oncogene activation or other forms of stress.Moreover, ARF-BP1 may prove to be an especially
aluable target for therapeutic intervention. Agents that
ctivate the p53 tumor suppression pathway, including
utlin, a small molecule antagonist of Mdm2 (Vassilev
t al., 2004), are currently being tested for their poten-
ial in cancer therapy. However, the utility of these
gents is limited to tumors that maintain a functional
53 pathway, a significant restriction given that p53
utations are found in more than 50% of human can-
ers. In contrast, since ARF-BP1 inactivation induces
rowth arrest in p53 null cells and also activates p53-
ependent apoptosis in p53 wild-type cells, inhibitors
f ARF-BP1 should suppress tumor cell growth regard-
ess of p53 status.
xperimental Procedures
lasmids
o clone the cDNA of ARF-BP1, five overlapping cDNA sequences
hat cover the full-length ARF-BP1 were amplified by PCR from
arathon-Ready HeLa cDNA (Clontech, BD Biosciences) and sub-
loned into pcDNA3.1/V5-His-Topo vector (Invitrogen). After se-
uence verification, the cDNA sequences were assembled and fur-
her cloned into expression vectors. To prepare mutant constructs
ARF-BP1(M), ARF-BP1(R), ARF-BP1M(R)], cDNA sequences corre-
ponding to different regions were amplified by PCR from above
onstructs using QuikChange Site-Directed Mutagenesis Kit (Stra-
agene) and subcloned into full-length ARF-BP1 using specific re-
triction enzymes. For the HA-ARF-Flag construct, the HA and Flag
equence were introduced to the N terminus and C terminus ARF,
espectively, by PCR and subcloned into the pCIN4 vector.
urification of ARF Complexes from Human Cells
he epitope-tagging strategy to isolate ARF-containing protein
omplexes from human cells was performed essentially as pre-
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al., 2000; Nikolaev et al., 2003). In brief, to obtain an HA-ARF-Flag-
expressing cell line, p53 null H1299 cells were transfected with
pCIN4-HA-ARF-Flag and selected for 2 weeks in 1 mg/ml G418.
The stable cell lines were chosen to expand for complex purifica-
tion if the expression levels of the ectopic ARF protein were close
to the levels of endogenous protein. Thus, the cells were grown in
DMEM with 10% fetal bovine serum and harvested near conflu-
ence. The cell pellet was then suspended in buffer A (10 mM
HEPES [pH 7.9], 10 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.5 mM
PMSF, and protein inhibitor mixture). The cells were allowed to
swell on ice for 15 min, after which 10% NP40 was added to a final
concentration of 0.5%. The tube was vigorously vortexed for 1 min.
The homogenate was centrifuged for 10 min at 4000 rpm. The
nuclear pellet was resuspended in ice-cold buffer C (20 mM HEPES
[pH 7.9], 0.4 M NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, and
protein inhibitor mixture), and the tube was vigorously rocked at
4°C for 45 min. The nuclear extract was diluted with buffer D (20
mM HEPES [pH 7.9], 1 mM EDTA) to the 100 mM final NaCl concen-
tration and ultracentrifuged at 25,000 rpm for 2 hr at 4°C. After
being filtered with 0.45 m syringe filters, the supernatants were
used as nuclear extracts for immunoprecipitations by anti-Flag an-
tibody-conjugated M2 agarose. The bound polypeptides eluted
with the Flag peptide were further affinity purified by anti-HA anti-
body-conjugated agarose. The final elutes from the HA-beads with
HA peptides were resolved by SDS-PAGE on a 4%–20% gradient
gel for silver staining or colloidal blue staining analysis. Specific
bands were cut out from the gel and subjected to mass spectrome-
try peptide sequencing.
Ablation of Endogenous ARF-BP1 by RNAi in Human Cells
p53 null cell lines (H1299 and Saos-2) and p53-expressing cells
(U2OS, MCF-7, NHF-1, and A549) were maintained in DMEM me-
dium supplemented with 10% fetal bovine serum. The HCT116 and
HCT116-p53−/− cell lines were kindly provided by B. Vogelstein’s
lab. The RNAi-mediated ablation of endogenous ARF-BP1 was per-
formed essentially as previously described (Elbashir et al., 2001;
Nikolaev et al., 2003). A 21 nucleotide siRNA duplex with 3#dTdT
overhangs corresponding to ARF-BP1 mRNA (ARF-BP1 1) (AAU
UGCUAUGUCU CUGGGACA) was synthesized (Dharmacon). The
same sequence (ARF-BP1 1 mutant) with two nucleotides changed
(AAUUGCCAUGUAUCUGGGACA) was used as a specific RNAi
control. The FACS analysis data represent the mean of three exper-
iments with standard deviations indicated. RNAi transfections were
performed using Oligofectamine reagent. The siRNAs of COP1 and
Pirh2 were used as previously reported (Dornan et al., 2004).
Supplemental Data
The Supplemental Data include Supplemental Experimental Pro-
cedures and thirteen figures and can be found with this article on-
line at http://www.cell.com/cgi/content/full/121/7/1071/DC1/.
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